Retraction notice to “Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A(H1N1)2009 virus infection in mice” (Antiviral Research (2012) 93(2) (219–224), (S0166354211005195) (10.1016/j.antiviral.2011.11.018));Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A(H1N1)2009 virus infection in mice

Antiviral Research

Volumn 93, Issue 2, 2012, Pages 219-224

  Tarasov, Sergey A ^b   Zarubaev, Vladimir V ^a   Gorbunov, Evgeniy A ^b   Sergeeva, Svetlana A ^b   Epstein, Oleg I ^b  

^a Influenza Research Institute   (Russian Federation)

^b R and D Department   (Russian Federation)

Author keywords

Antibodies to interferon; Antiviral activity; Influenza; Pandemic

Indexed keywords

ANAFERON; ANTIVIRUS AGENT; OSELTAMIVIR; PLACEBO; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; FEMALE; INFLUENZA VIRUS A H1N1; LIFESPAN; LUNG; LUNG PARENCHYMA; LUNG STRUCTURE; MORTALITY; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL; WEIGHT REDUCTION;

ANIMALIA; INFLUENZA A VIRUS; INFLUENZAVIRUS A; MUS; ORTHOMYXOVIRIDAE;

EID: 84856113140     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2019.02.011     Document Type: Erratum

References (42)

1. Alleva L.M., Cai C., Clark I.A. Using complementary and alternative medicines to target the host response during severe influenza. Evid. Based Complement. Altern. Med. 2010, 7:501-510.
2. Bernasconi D., Amici C., La Frazia S., Ianaro A., Santoro M.G. The IkappaB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells. J. Biol. Chem. 2005, 280(25):24127-24134.
3. Carey M.A., Bradbury J.A., Seubert J.M., Langenbach R., Zeldin D.C., Germolec D.R. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J. Immunol. 2005, 175:6878-6884.
4. Influenza C.D.C. Activity - United States and worldwide. Morb. Mortal. Wkly. Rep. 2008, 57:1046-1049.
5. Chan P.A., Connell N.T., Gabonay A.M., Westley B., Larkin J.M., LaRosa S.P., Chapin K., Mermel L. Oseltamivir-resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient. Clin. Microbiol. Infect. 2010, 16(10):1576-1578.
6. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., Gubareva L.V., Xu X., Bridges C.B., Uyeki T.M. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team 2009, 360(25):2605-2615.
7. Dawson T.C., Beck M.A., Kuziel W.A., Henderson F., Maeda N. Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am. J. Pathol. 2000, 156:1951-1959.
8. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., St George K., Epperson S., Brammer L., Klimov A.I., Bresee J.S., Fry A.M. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009, 301:1034-1041.
9. Disease Outbreak News [abbreviated and edited]. World Health Organisation (Updated 21 May 2010). Available from. http://www.who.int/csr/don/2010_05_21/en/index.html.
10. Epstein O.I., Dugina J.L., Tarasov S.A., Sergeeva S.A. Inflamation immunopharmacology: new tools for old diseases antiviral activity of anaferon for children in pandemic A/H1N1 in mice 16th IUPHAR World Congress of Basis and Clinical Pharmacology. 17-23 July 2010 2010, Copenhagen, Denmark, Abstract 1798.
11. Epstein, O.I., Pharmacology of ultralow doses of antibodies to endogenous regulators of functions. Moscow: RAMS Publishing House, 2005, p. 226.
12. Epstein, O.I., Ultralow doses (history of one research). Moscow, RAMS Publishing House, 2008, p. 336.
13. Garigliany M.M., Habyarimana A., Lambrecht B., Van de Paar E., Cornet A., vandenBerg T., Desmecht D. Influenza A strain-dependent pathogenesis in fatal H1N1 and H5N1 subtype infections of mice. Emerg. Infect. Dis. 2010, 16:595-603.
14. Hauge S.H., Dudman S., Borgen K., Lackenby A., Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg. Infect. Dis. 2009, 15:155-162.
15. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold?. Clin. Infect. Dis. 2009, 1:3-13.
16. Hayden F.G. Combination antiviral therapy for respiratory virus infections. Antiviral Res. 1996, 29:45-48.
17. Kudin M.V., Tarasov S.A., Kachanova M.V., Skripkin A.V., Fedorov Y.N. Anaferon (pediatric formulation) in prophylactics of acute respiratory viral infection in children. Bull. Exp. Biol. Med. 2009, 148:279-282.
18. Kurokawa M., Watanabe W., Shimizu T., Sawamura R., Shiraki K. Modulation of cytokine production by 7-hydroxycoumarin in vitro and its efficacy against influenza infection in mice. Antiviral Res. 2010, 85:373-380.
19. Lapinsky S.E. Epidemic viral pneumonia. Curr. Opin. Infect. Dis. 2010, 23:139-144.
20. Ludwig S. Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J. Antimicrob. Chemother. 2009, 64(1):1-4.
21. Martyushev-Poklad A.V., Kotelnikova M.P., Uchaikin V.F., Dugina J.L., Epstein O.I., Sergeeva S.A. A novel antiviral based on oral antibodies: clinical benefits in paediatric upper respiratory infections. Clin. Microbiol. Infect. 2004, 10:125-126.
22. Moscona A. Medical management of influenza infection. Annu. Rev. Med. 2008, 59:397-413.
23. Moscona A. Oseltamivir resistance-disabling our influenza defenses. N. Engl. J. Med. 2005, 353:2633-2636.
24. Narasaraju T., Sim M.K., Ng H.H., Phoon M.C., Shanker N., Lal S.K., Chow V.T. Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis. Microbes Infect. 2009, 11:2-11.
25. Nimmerjahn F., Dudziak D., Dirmeier U., Hobom G., Riedel A., Schlee M., Staudt L.M., Rosenwald A., Behrends U., Bornkamm G.W., Mautner J. Active NF-kappaB signalling is a prerequisite for influenza virus infection. J. Gen. Virol. 2004, 85(Pt 8):2347-2356.
26. Obraztsova E.V., Osidak L.V., Golovacheva E.G., et al. Interferon status in children with acute respiratory infections. Interferon therapy. Bull. Exp. Biol. Med. 2009, 148:22-26.
27. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27:493-497.
28. Rello J., Rodríguez A., Ibañez P., Socias L., Cebrian J., Marques A., Guerrero J., Ruiz-Santana S., Marquez E., Del Nogal-Saez F., Alvarez-Lerma F., Martínez S., Ferrer M., Avellanas M., Granada R., Maraví-Poma E., Albert P., Sierra R., Vidaur L., Ortiz P., Prieto del Portillo I., Galván B., León A., Gil C. Intensive care adult patients with severe respiratory failure caused by Influenza (H1N1)v in Spain. Crit. Care 2009, 13:R148.
29. Sanders C.J., Doherty P.C., Thomas P.G. Respiratory epithelial cells in innate immunity to influenza virus infection. Cell Tissue Res. 2011, 343:13-21.
30. Schmitz N., Kurrer M., Bachmann M.F., Kopf M. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J. Virol. 2005, 79:6441-6448.
31. Sergeev A.N., P'iankov O.V., Shishkina L.N., Duben' L.G., Petrishchenko V.A., Zhukov V.A., P'iankova O.G., Sviatchenko L.I., Sherstoboev Elu, Karimova T.V., Martiushev-Poklad A.V., Sergeeva S.A., Epshteǐn O.I., Glotov A.G., Glotova T.I. Antiviral activity of oral ultralow doses of antibodies to gamma-interferon: experimental study of influenza infection in mice. Antibiot. Khimioter. 2004, 49:7-11.
32. Sherstoboev E.Y., Masnaya N.M., Churin A.A., Borsuk O.S., Martyushev A.V., Epstein O.I. Immunotropic effects of potentiated antibodies to human interferon-γ. Bull. Exp. Biol. Med. 2003, 1:67-69.
33. Shishkina L.N., Sergeev A.N., Kabanov A.S., Skarnovich M.O., Evtin N.K., Mazurkova N.A., Sergeev A.A., Belopolskaya M.V., Kheyfets I.A., Dugina J.L., Tarasov S.A., Sergeeva S.A., Epstein O.I. Study of efficiency of therapeutic and preventive anaferon (pediatric formulation) in mice with influenza infection. Bull. Exp. Biol. Med. 2008, 146:763-765.
34. Shishkina L.N., Skarnovich M.O., Kabanov A.S., Sergeev A.A., Olkin S.E., Tarasov S.A., Belopolskaya M.V., Sergeeva S.A., Epstein O.I., Malkova E.M., Stavsky E.A., Drozdov I.G. Antiviral Activity of Anaferon (Pediatric Formulation) in Mice Infected with Pandemic Influenza Virus A(H1N1/09). Bull. Exp. Biol. Med. 2010, 149:612-614.
35. Tarasov, S., Dugina, J., Anaferon in pediatric febrile viral infections: a brief review of the results of clinical trials in Russia, 25th International Congress of Pediatrics «for the health and well-being of our children», 25-30 August 2007, Athens, Greece (Abstract 0531).
36. Tarasov, S., Dugina, J., Oral antibody to interferon gamma in ultra low doses: clinical efficacy and interferon stimulation in patients with upper respiratory viral infections, 5th Congress of European Pharmacology Society, 13-17 July 2008, Manchester, UK (Abstract C026).
37. Tarasov, S., Zarubaev, V., Tafani, J., Dugina, J., Sergeeva, S., Epstein, O., Antibodies to interferon-gamma in ultra-low doses: a new option for pandemic influenza, 20th European Congress of Microbiology and infections Diseases, 10-13 April 2010, Vienna, Austria (Abstract P1106).
38. Tarasov, S.A., Mashkina, M.V., Development ELISA for quantitative measurement natural autoantibodies - potent endogeneous target of ultralow doses of antibodies, 2nd Moscow International Conference " Immunophysiology: natural autoimmunity in physiology and pathology" , 26-28 September 2008, Moscow, Russia (Abstract P203).
39. To K., Hung I.F., Li I.W., Lee K.L., Koo C.K., Yan W.W., Liu R., Ho K.Y., Chu K.H., Watt C.L., Luk W.K., Lai K.Y., Chow F.L., Mok T., Buckley T., Chan J.F., Wong S.S., Zheng B., Chen H., Lau C.C., Tse H., Cheng V.C., Chan K.H., Yuen K.Y. Delayed clearance of viral load, marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin. Infect. Dis. 2010, 50:850-859.
40. Vasil'ev A.N., Sergeeva S.A., Kachanova M.V. Use of ultralow doses of antibodies to gamma-interferon in the treatment and prophylaxis of viral infections. Antibiot Khimioter 2008, 53:32-35.
41. Wei L., Sandbulte M.R., Thomas P.G., Webby R.J., Homayouni R., Pfeffer L.M. NFkappaB negatively regulates interferon-induced gene expression and anti-influenza activity. J. Biol. Chem. 2006, 281(17):11678-11684.
42. Woo P.C., Tung E.T., Chan K.H., Lau C.C., Lau S.K., Yuen K.Y. Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies. J. Infect. Dis. 2010, 201:346-353.